We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Down on Business Divestment Declaration
Read MoreHide Full Article
Shares of Thermo Fisher Scientific Inc. (TMO - Free Report) slipped 1.25% at yesterday’s close following the company’s announcement of its plans to divest its Anatomical Pathology business. PHC Holdings, a Japanese healthcare company, has agreed to buy this business for a cash consideration of $1.14 billion.
Thermo Fisher expects this transaction to close in the second quarter of 2019, subject to customary closing conditions and applicable regulatory approvals.
Notably, the Anatomical Pathology business of Thermo Fisher comes under its Specialty Diagnostics segmentthat serves customers in healthcare and clinical laboratories. Last year, this segment contributed more than 15% to the company’s top line. Over the past year, this segment had steadily generated positive revenue growth.
The Anatomical Pathology subsegment provides microscope slides, instruments and consumables. It has approximately 1,200 employees at locations across the United States, Europe and China. The business generates approximately $350 million in annual revenues.
Financial Impact of the Deal
Thermo Fisher expects the net dilution of this divestment to 2019 adjusted earnings per share to be approximately 10 cents. The company is going to incorporate this into its 2019 financial guidance that will be provided during the first-quarter 2019 earnings call, scheduled on Jan 30.
Price Performance
Over the past year, the company’s share price has outperformed its industry. The stock has gained 10.8% compared with the industry’s 2% rise.
Zacks Rank and Key Picks
Thermo Fisher carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Omnicell, Inc. (OMCL - Free Report) , Amedisys, Inc. (AMED - Free Report) and Illumina, Inc. (ILMN - Free Report) .
Amedisys’ long-term earnings growth rate is projected at 18.8%. The stock carries a Zacks Rank of 2.
Illumina’s long-term earnings growth rate is expected at 20.9%. The stock is a Zacks #2 Ranked player.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Thermo Fisher (TMO) Down on Business Divestment Declaration
Shares of Thermo Fisher Scientific Inc. (TMO - Free Report) slipped 1.25% at yesterday’s close following the company’s announcement of its plans to divest its Anatomical Pathology business. PHC Holdings, a Japanese healthcare company, has agreed to buy this business for a cash consideration of $1.14 billion.
Thermo Fisher expects this transaction to close in the second quarter of 2019, subject to customary closing conditions and applicable regulatory approvals.
Notably, the Anatomical Pathology business of Thermo Fisher comes under its Specialty Diagnostics segmentthat serves customers in healthcare and clinical laboratories. Last year, this segment contributed more than 15% to the company’s top line. Over the past year, this segment had steadily generated positive revenue growth.
Thermo Fisher Scientific Inc. Price
Thermo Fisher Scientific Inc. Price | Thermo Fisher Scientific Inc. Quote
The Anatomical Pathology subsegment provides microscope slides, instruments and consumables. It has approximately 1,200 employees at locations across the United States, Europe and China. The business generates approximately $350 million in annual revenues.
Financial Impact of the Deal
Thermo Fisher expects the net dilution of this divestment to 2019 adjusted earnings per share to be approximately 10 cents. The company is going to incorporate this into its 2019 financial guidance that will be provided during the first-quarter 2019 earnings call, scheduled on Jan 30.
Price Performance
Over the past year, the company’s share price has outperformed its industry. The stock has gained 10.8% compared with the industry’s 2% rise.
Zacks Rank and Key Picks
Thermo Fisher carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Omnicell, Inc. (OMCL - Free Report) , Amedisys, Inc. (AMED - Free Report) and Illumina, Inc. (ILMN - Free Report) .
Omnicell’s long-term earnings growth rate is estimated at 11.8%. The stock flaunts a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Amedisys’ long-term earnings growth rate is projected at 18.8%. The stock carries a Zacks Rank of 2.
Illumina’s long-term earnings growth rate is expected at 20.9%. The stock is a Zacks #2 Ranked player.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>